Abstract
Background Genital herpes simplex virus (HSV) type 1 and 2 infections are lifelong and can cause symptomatic genital ulcer disease (GUD). HSV-2 almost always causes sexually transmitted genital infection, while HSV-1 mainly causes oral infection but can be sexually transmitted to cause genital infection. This study estimated genital infection with both HSV types and associated GUD globally in 2020, breaking down the data by World Health Organization (WHO) region and sex for females and males.
Methods A calibrated mathematical model was employed to generate estimates for the incidence and prevalence of HSV-2 infection, genital HSV-1 infection, and GUD caused by both HSV types. Estimates for non-genital infections caused by HSV-1 were also generated. Model input was derived from a comprehensive systematic review and meta-analyses of HSV prevalence data for all WHO regions.
Results Globally in 2020 there were 25.6 million (95% uncertainty interval (UI): 23.1-29.4 million) people aged 15 to 49 years with new HSV-2 infections and 519.5 million (95% UI: 464.3-611.3 million), or 13.3% (95% UI: 11.9-15.6%), with existing (prevalent) HSV-2 infections. In addition, there were 16.8 million (95% UI: 10.6-22.4 million) people aged 15-49 years with new genital HSV-1 infections and 376.2 million (95% UI: 235.6-483.5 million), or 10.2% (95% UI: 6.4-13.1%), with prevalent genital HSV-1 infections. The estimated number of people aged 15 to 49 years with at least one episode of HSV-attributable genital ulcer disease in 2020 was 187.9 million (95% UI: 116.0-291.8 million) for HSV-2 and 16.7 million (95% UI: 9.3-25.2 million) for HSV-1, totaling 204.6 million (95% UI: 132.3-306.5).
Conclusion Genital HSV infections have a high incidence and prevalence worldwide, contributing to a significant GUD disease burden. New prevention and treatment measures, such as prophylactic and therapeutic HSV vaccines, are critically needed to control HSV infections and reduce the associated disease burden.
Competing Interest Statement
MH, SM, AA, AMMO, SLG, JR, and LJA declare no competing interests. KJL reports grants from WHO during the conduct of the study and outside the submitted work. KJL reports a grant from GSK outside the submitted work.
Funding Statement
This publication was supported by the World Health Organization (Global HIV, Hepatitis and STIs Programmes) through a grant from USAID. WHO commissioned the study, advised as required, helped with redrafts, and approved manuscript submission. MH, SM, AA, AMMO, and LJA are grateful for research support provided by the Biomedical Research Program and by the Biostatistics, Epidemiology, and the Biomathematics Research Core at Weill Cornell Medicine-Qatar. KJL thanks the National Institute for Health Research (NIHR) and the Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation at the University of Bristol, in partnership with the UK Health Security Agency (UKHSA), for research support. The original systematic reviews for HSV-1 and HSV-2 were funded in part by grant numbers ARG01-0524-230321 from the Qatar Research, Development, and Innovation Council and NPRP9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated, including the NHS, the NIHR, the Department for Health and Social Care, the UKHSA, and the WHO.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
This mathematical modeling study is based on data that are publicly available. Data is provided within the manuscript or supplementary information files. No Institutional Review Board clearance was required to use these data.
List of abbreviations
- CI
- Confidence intervals
- GATHER
- Guidelines for Accurate and Transparent Health Estimates Reporting
- GUD
- Genital ulcer disease
- HSV
- Herpes simplex virus
- HSV-1
- Herpes simplex virus type 1
- HSV-2
- Herpes simplex virus type 2
- UI
- Uncertainty interval
- WHO
- World Health Organization
